Drug Profile
Plinabulin - BeyondSpring Pharmaceuticals
Alternative Names: BPI 2358; NPI 2358Latest Information Update: 29 Mar 2024
Price :
$50
*
At a glance
- Originator Nereus Pharmaceuticals
- Developer BeyondSpring Pharmaceuticals; Big Ten Cancer Research Consortium; M. D. Anderson Cancer Center; Nereus Pharmaceuticals; Rutgers Cancer Institute of New Jersey
- Class Antineoplastics; Imidazoles; Piperazines; Small molecules
- Mechanism of Action Antigen presenting cell stimulants; Guanine nucleotide exchange factor stimulants; Tubulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Neutropenia
- Phase III Non-small cell lung cancer
- Phase II Small cell lung cancer
- Phase I/II Cancer
- Preclinical Bladder cancer; Breast cancer; Gastric cancer; Glioblastoma; Sickle cell anaemia; Soft tissue sarcoma
- No development reported Brain cancer; Solid tumours
Most Recent Events
- 25 Mar 2024 Phase-II clinical trials in Small cell lung cancer (Late-stage disease, First-line therapy, Combination therapy) (IV) (NCT05745350)
- 01 Nov 2023 Pharmacodynamics data from a preclinical trial in Glioblastoma released by the BeyondSpring Pharmaceuticals
- 07 Jun 2023 Efficacy and adverse events data from phase-II trial in Neutropenia released by BeyondSpring